Clinical Trials
15
Trial Phases
4 Phases
Drug Approvals
135
Drug Approvals
LAZCLUZE lazertinib 80 mg film-coated tablets blister pack (444772)
- Product Name
- LAZCLUZE lazertinib 80 mg film-coated tablets blister pack
- Approval Date
- Apr 15, 2025
LAZCLUZE lazertinib 240 mg film-coated tablets blister pack (444770)
- Product Name
- LAZCLUZE lazertinib 240 mg film-coated tablets blister pack
- Approval Date
- Apr 15, 2025
LAZCLUZE lazertinib 80 mg film-coated tablets bottle (444773)
- Product Name
- LAZCLUZE lazertinib 80 mg film-coated tablets bottle
- Approval Date
- Apr 15, 2025
LAZCLUZE lazertinib 240 mg film-coated tablets bottle (444771)
- Product Name
- LAZCLUZE lazertinib 240 mg film-coated tablets bottle
- Approval Date
- Apr 15, 2025
DARZALEX daratumumab 100 mg/5 mL concentrated solution for infusion vial (455605)
- Product Name
- DARZALEX daratumumab 100 mg/5 mL concentrated solution for infusion vial
- Approval Date
- Mar 28, 2025
DARZALEX daratumumab 400 mg/20 mL concentrated solution for infusion vial (455606)
- Product Name
- DARZALEX daratumumab 400 mg/20 mL concentrated solution for infusion vial
- Approval Date
- Mar 28, 2025
Cellular Therapies - T cells-Ciltacabtagene autoleucel, cryopreserved-T-CARVYKTI - Janssen-Cilag Pty Ltd - Injection, intravenous infusion - Bag (481782)
- Product Name
- T cells-Ciltacabtagene autoleucel, cryopreserved-T-CARVYKTI
- Approval Date
- Mar 5, 2025
SETRELVO ustekinumab 90 mg/ 1 mL solution for injection pre-filled pen (One-Press patient-controlled injector) (462464)
- Product Name
- SETRELVO ustekinumab 90 mg/ 1 mL solution for injection pre-filled pen (One-Press patient-controlled injector)
- Approval Date
- Oct 18, 2024
SETRELVO ustekinumab 45 mg/ 0.5 mL solution for injection pre-filled pen (One-Press patient-controlled injector) (462457)
- Product Name
- SETRELVO ustekinumab 45 mg/ 0.5 mL solution for injection pre-filled pen (One-Press patient-controlled injector)
- Approval Date
- Oct 18, 2024
TALVEY talquetamab 2 mg/mL solution for injection vial (409913)
- Product Name
- TALVEY talquetamab 2 mg/mL solution for injection vial
- Approval Date
- Sep 26, 2024
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2016-03-10
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 127
- Registration Number
- NCT01362426
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
- Conditions
- HIV-1
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 68
- Registration Number
- NCT01177059
Schizophrenia Treatment Adherence Investigation (STAI)
- Conditions
- Schizoaffective DisorderSchizophrenia
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 550
- Registration Number
- NCT01001481
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: PAD induction
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 107
- Registration Number
- NCT00872521
A Pilot Trial to Evaluate the Effect of Diet and Exercise in Renal Transplant Recipients on Tacrolimus
- Conditions
- Kidney TransplantionRenal Transplantion
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT00492661
- Prev
- 1
- 2
- 3
- Next
News
PAQ Therapeutics Secures $39M Series B Funding and Launches Phase 1 Trial for Novel KRAS G12D Degrader
• PAQ Therapeutics has raised $39 million in Series B financing co-led by MRL Ventures Fund and Bayland Capital, with participation from several other investors including Johnson & Johnson Innovation. • The company has initiated a Phase 1 clinical trial for PT0253, its lead candidate that selectively degrades KRAS G12D mutations, a known driver for various solid tumors with high unmet medical needs. • Preclinical data suggests PT0253 has best-in-class potential compared to existing agents targeting the same KRAS mutant, potentially offering more effective and durable treatment options for patients with lethal cancers.
Citryll Secures €85 Million in Series B Funding to Advance NET-Targeting Antibody CIT-013
Citryll BV raised €85 million in a Series B funding round co-led by Johnson & Johnson Innovation, Forbion, and Novartis Venture Fund to advance clinical development of CIT-013.
Wales Launches £100 Million Life Sciences Hub to Boost Innovation and Investment
• Wales establishes a major life sciences initiative with a £100 million investment fund, representing the largest sector-specific investment in the country's history. • Life Sciences Hub Wales secures Johnson & Johnson Innovation and GE Healthcare as anchor tenants, creating a collaborative ecosystem for academia, business, and healthcare sectors. • The initiative has already invested £20 million in strategic projects, including Simbec Research's expansion and ReNeuron's relocation of cell manufacturing operations to Wales.